Clinical trial of IMRTcombine with gimeracil capsule in the treatment of nasopharyngeal carcinoma

Clinical study of intensity-modulated radiotherapy combined with S-1 capsule in the treatment of nasopharyngeal carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008835

Enrollment

Unknown

Registered

2016-07-13

Start date

2016-07-13

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

1:intensity-modulated radiotherapy combined with S-1 capsule

2:Intensity modulated radiotherapy concurrent with cisplatin and 5-FU

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The primary treatment of nasopharyngeal squamous cell carcinoma confirmed by histology or cytology; 2. aged 18-65 years old; 3. The Karnofsky score is more than 70; 4. the expected survival time more than 3 months; 5. there are likely to be followed; 6. liver and kidney function, heart function, normal blood; 7. patient to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. active infection with severe or serious liver and kidney and hematopoietic system diseases; 2. patients with no measurable or measurable lesions; 3. symptomatic brain metastases; 4. bone metastases or pleural effusion were the only observed indicators; 5. poor compliance 6 other clinical trial drug withdrawal time is less than 4 weeks.

Design outcomes

Primary

Measure	Time frame
PFS;OS;	—

Secondary

Measure	Time frame
Adverse reactions;	—

Countries

China

Contacts

Public ContactWen Juyi

Navy General Hospital of PLA

wenuyi@126.com+86 18600310687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026